More than 15,400 NHS patients a year could gain access to new medicines following NICE's first threshold rise in 20+ years, according to our latest CONNIE report. 💊
Half of the 20 appraisals since April resulted in better outcomes for patients. The task now is to sustain that.
https://t.co/UTZ4GRC239
"A new treatment can mean more time, better quality of life and greater independence." Victoria Jordan, ABPI. We'll keep tracking the impact and working with @NICEcomms, government and the NHS. #AccessToMedicines
More than 15,400 NHS patients a year could benefit from new medicines they might otherwise have gone without, following NICE's first threshold rise in 20+ years.
💊 Our latest CONNIE report has the early evidence. https://t.co/VfxENFQLeP
At the end of a huge week in Washington DC, I had the privilege of pouring the opening pint at The Two Georges, the new pub in the British Embassy.
A fitting end to an inspiring visit championing British life sciences and UK–US collaboration in health innovation. I return energised by the ambition, inspired by the partnerships and convinced Britain has what it takes to lead the next generation of healthcare.
Our NHS 10 Year Plan sets out three big shifts: hospital to community, analogue to digital, and sickness to prevention.
Underpinning these are five big bets: data, AI, genomics, wearables and robotics.
Throughout the week, five propositions have been central to my championing the UK and our ambitions:
Regulation as the enabler. Safe, fast and trusted. Innovation moves at the speed of trust. Safety and innovation are not competing priorities. The right regulation builds confidence, enables progress and accelerates adoption.
Technology as triage. Identifying risk earlier, prioritising need and getting patients the right care, in the right place, at the right time.
AI turning the ‘we dream’ into the ‘we do’. Moving from promise to practice in diagnosis, drug discovery, clinical trials and hyper-personalised care.
The special relationship delivering results. Our UK–US pharmaceuticals agreement shows the practical value of partnership, strengthening investment, innovation and access to breakthrough medicines.
Health innovation needs innovation of thought too. Rethinking rare diseases, the digitisation of health, our future NHS, clinical trials and drug discovery. Unlocking data as an unending source of national wealth, building UK sovereign capability and achieving more with global partners than we could alone. Not just doing things faster, but thinking differently about what’s possible.
The UK has it all. World-leading science, exceptional universities, pioneering businesses, respected regulators and the unique strength of our NHS.
We stand ready to do even more. And we must.
Our Life Sciences Sector Plan is how we turn ambition into delivery: attracting investment, accelerating research and trials, growing British businesses and ensuring innovations developed here reach patients here.
We must lead not only in discovering the next generation of treatments, but in adopting them.
Innovation travels at the speed of trust. And only matters when it travels fastest to reaching patients.
Well worth raising a glass to.
Spending more on medicines doesn't have to come at the expense of other NHS priorities. Sophie Caseby responds in @HSJnews: a 10-year commitment is an investment in better patient outcomes and UK research. Affordability and access aren't opposites. 👇 https://t.co/fMDtpvRM2V
Recruitment into UK industry clinical trials has fallen for a fifth consecutive year – just 17,618 people took part in 2025/26.
Faster set-up is welcome, but it isn’t yet getting more patients into trials. Our report sets out what must change 👇
https://t.co/Zy4dyBZzVm
Approval isn’t the same as access. Prescribing of non-statin cholesterol-lowering medicines varied 8- to 10-fold between NHS boards in Scotland. Earlier planning can help ensure services are ready when the SMC publishes its advice. Read more @LCPHealth: https://t.co/fDKfUK9Skz
In Scotland, everyone should have equitable access to medicines the Scottish Medicines Consortium has already judged effective and good value.
Our new report, supported by @LCPHealth, compares prescribing across all 14 NHS boards.
https://t.co/r7oaof7Ktc
#MedicinesAccess #NHSScotland
We welcome today's #Budget2026 move to remove the VAT charge on medicines that companies provide free of charge – a significant win for patients, protecting continuity of care and supporting clinical research in the UK. https://t.co/Atqz8stY1I
Join @ftlive's Global Pharma & Biotech Summit to connect with the senior executives, investors and policymakers shaping the future of life sciences.
Register now: https://t.co/l5ovqv6uJS #FTPharma
Flu can be serious, especially for those at highest risk of becoming seriously ill.
If you're eligible for a free NHS flu vaccine, don't wait for winter to get it.
It's one of the best ways to protect yourself.
Book online now or on the NHS App: https://t.co/JTC6h2WOZh
UK pharmaceutical R&D investment: £9.3bn in 2024. Growing at 3.3 per cent a year, against a global 6.7 per cent. An estimated £3.8bn of investment foregone since 2020. https://t.co/UqvzUTwRtk
Vaccines protect people at every stage of life. Our 3 new infographics explore the value of vaccination and the latest coverage data in Wales and Scotland. All available here: https://t.co/ooIwuGAfuc @NHSEngland#VaccinesWork
Join FT Live's Global Pharma and Biotech Summit in London on 10-11 November. Meet leaders from Novartis, GSK, Novo Nordisk, Takeda, Bayer, the ABPI, MHRA and more. See who's attending: https://t.co/Rb2jQm0YQM
Less than 4 weeks to go! Register now and save 20% with code ABPI: https://t.co/7ijo6vKZdr #FTPharma
The strategy addresses several priorities the ABPI set out in its December 2024 report, Enhancing the role of UK medicine regulation, including faster, more predictable regulatory decisions, clearer performance reporting, and closer working between the MHRA and NICE. https://t.co/07VPGWUV6g
We’re in Parliament for #WestminsterVaccinationDay 🎉
Vaccination is a powerful and effective public health intervention. It builds NHS resilience, helps cut waiting lists and supports productivity and growth.
Thanks to all joining us! @NHSEngland@DanielZeichner
Equality is also a lot more complicated than simple patient numbers. Rare diseases are individually rare, but collectively common: 1 in 17 ppl have one. #KFLifeSciences
Tackling inequalities in healthcare has got to involve a smart blend of national standards and local decision making, says @TorbettR at the @TheKingsFund conference today #KFLifeSciences